BidaskClub lowered shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a sell rating to a strong sell rating in a report published on Thursday, January 11th.
ZIOP has been the subject of several other research reports. HC Wainwright set a $10.00 price target on shares of ZIOPHARM Oncology and gave the stock a buy rating in a research note on Thursday, December 14th. ValuEngine lowered shares of ZIOPHARM Oncology from a hold rating to a sell rating in a research note on Friday, September 15th. Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a hold rating to a buy rating and set a $5.25 price objective for the company in a research note on Friday, November 10th. Finally, Raymond James Financial reiterated a hold rating on shares of ZIOPHARM Oncology in a research note on Monday, December 11th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. ZIOPHARM Oncology has an average rating of Hold and an average price target of $12.67.
ZIOPHARM Oncology (NASDAQ ZIOP) traded down $0.08 during trading hours on Thursday, reaching $4.28. 1,372,766 shares of the company’s stock traded hands, compared to its average volume of 1,571,497. The stock has a market cap of $607.60, a price-to-earnings ratio of -8.23 and a beta of 1.44. ZIOPHARM Oncology has a 52-week low of $3.77 and a 52-week high of $7.88.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.13) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). The firm had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $1.66 million. The company’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the business posted ($0.11) EPS. equities research analysts expect that ZIOPHARM Oncology will post -0.54 earnings per share for the current year.
In other news, CEO Laurence James Neil Cooper purchased 6,440 shares of the business’s stock in a transaction on Wednesday, November 8th. The stock was purchased at an average cost of $4.68 per share, with a total value of $30,139.20. Following the acquisition, the chief executive officer now directly owns 1,083,731 shares in the company, valued at $5,071,861.08. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 10.40% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of ZIOP. Schwab Charles Investment Management Inc. lifted its holdings in shares of ZIOPHARM Oncology by 7.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 580,149 shares of the biotechnology company’s stock worth $3,609,000 after acquiring an additional 41,860 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of ZIOPHARM Oncology by 5.6% during the 2nd quarter. Rhumbline Advisers now owns 151,096 shares of the biotechnology company’s stock worth $940,000 after acquiring an additional 8,029 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of ZIOPHARM Oncology by 2.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 611,533 shares of the biotechnology company’s stock worth $3,804,000 after acquiring an additional 13,127 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of ZIOPHARM Oncology by 6.3% during the 2nd quarter. Legal & General Group Plc now owns 44,655 shares of the biotechnology company’s stock worth $279,000 after acquiring an additional 2,666 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. bought a new stake in shares of ZIOPHARM Oncology during the 2nd quarter worth $264,000. 40.23% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “ZIOPHARM Oncology (NASDAQ:ZIOP) Downgraded to Strong Sell at BidaskClub” was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.thelincolnianonline.com/2018/01/21/ziopharm-oncology-ziop-downgraded-to-strong-sell-at-bidaskclub-updated.html.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.